NovaBridge Holds $210.8M; Givastomig Targets Phase 3 in Q4 2026, VIS-101 Heads to Phase 2b in H2 2026
NovaBridge ended 2025 with $210.8 million in cash, expected to fund operations through 2028 and support pipeline expansion. Lead assets givastomig showed a 75% objective response rate and 16.9-month median progression-free survival in gastric cancer, while VIS-101 delivered durable wet-AMD responses and plans Phase 2b initiation in H2 2026.
1. Financial Position
NovaBridge closed 2025 with $210.8 million in cash and cash equivalents, providing funding for operations through at least 2028 without additional financing. This strong liquidity underpins upcoming clinical programs and supports strategic pipeline development.
2. Givastomig Pipeline Progress
Givastomig, a bispecific CLDN18.2 X 4-1BB antibody for first-line metastatic gastric cancer, achieved a 75% objective response rate and 16.9-month median progression-free survival in Phase 1b expansion (n=52). The FDA confirmed potential eligibility for an Accelerated Approval pathway, with registrational Phase 3 initiation possible in Q4 2026.
3. VIS-101 Pipeline Progress
VIS-101, a dual VEGF-A X ANG-2 inhibitor for wet-AMD, demonstrated rapid and durable treatment responses in Phase 2a, with approximately two-thirds of patients retreatment-free at four months and half at six months. NovaBridge plans to launch Phase 2b studies in H2 2026 to further assess efficacy and durability.
4. Governance and Leadership
The company expanded its Board of Directors with five new members, including appointments to its Research and Development Committee, and added key executives such as a new Chief Financial Officer. These governance enhancements aim to bolster oversight and execution of NovaBridge’s global biotech strategy.